Cargando…
One-Year Review in Cardiac Arrest: The 2022 Randomized Controlled Trials
Cardiac arrest, one of the leading causes of death, accounts for numerous clinical studies published each year. This review summarizes the findings of all the randomized controlled clinical trials (RCT) on cardiac arrest published in the year 2022. The RCTs are presented according to the following c...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054058/ https://www.ncbi.nlm.nih.gov/pubmed/36983236 http://dx.doi.org/10.3390/jcm12062235 |
_version_ | 1785015561391964160 |
---|---|
author | Penna, Alessio Magliocca, Aurora Merigo, Giulia Stirparo, Giuseppe Silvestri, Ivan Fumagalli, Francesca Ristagno, Giuseppe |
author_facet | Penna, Alessio Magliocca, Aurora Merigo, Giulia Stirparo, Giuseppe Silvestri, Ivan Fumagalli, Francesca Ristagno, Giuseppe |
author_sort | Penna, Alessio |
collection | PubMed |
description | Cardiac arrest, one of the leading causes of death, accounts for numerous clinical studies published each year. This review summarizes the findings of all the randomized controlled clinical trials (RCT) on cardiac arrest published in the year 2022. The RCTs are presented according to the following categories: out-of- and in-hospital cardiac arrest (OHCA, IHCA) and post-cardiac arrest care. Interestingly, more than 80% of the RCTs encompassed advanced life support and post-cardiac arrest care, while no studies focused on the treatment of IHCA, except for one that, however, explored the temperature control after resuscitation in this population. Surprisingly, 9 out of 11 RCTs led to neutral results demonstrating equivalency between the newly tested interventions compared to current practice. One trial was negative, showing that oxygen titration in the immediate pre-hospital post-resuscitation period decreased survival compared to a more liberal approach. One RCT was positive and introduced new defibrillation strategies for refractory cardiac arrest. Overall, data from the 2022 RCTs discussed here provide a solid basis to generate new hypotheses to be tested in future clinical studies. |
format | Online Article Text |
id | pubmed-10054058 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100540582023-03-30 One-Year Review in Cardiac Arrest: The 2022 Randomized Controlled Trials Penna, Alessio Magliocca, Aurora Merigo, Giulia Stirparo, Giuseppe Silvestri, Ivan Fumagalli, Francesca Ristagno, Giuseppe J Clin Med Review Cardiac arrest, one of the leading causes of death, accounts for numerous clinical studies published each year. This review summarizes the findings of all the randomized controlled clinical trials (RCT) on cardiac arrest published in the year 2022. The RCTs are presented according to the following categories: out-of- and in-hospital cardiac arrest (OHCA, IHCA) and post-cardiac arrest care. Interestingly, more than 80% of the RCTs encompassed advanced life support and post-cardiac arrest care, while no studies focused on the treatment of IHCA, except for one that, however, explored the temperature control after resuscitation in this population. Surprisingly, 9 out of 11 RCTs led to neutral results demonstrating equivalency between the newly tested interventions compared to current practice. One trial was negative, showing that oxygen titration in the immediate pre-hospital post-resuscitation period decreased survival compared to a more liberal approach. One RCT was positive and introduced new defibrillation strategies for refractory cardiac arrest. Overall, data from the 2022 RCTs discussed here provide a solid basis to generate new hypotheses to be tested in future clinical studies. MDPI 2023-03-14 /pmc/articles/PMC10054058/ /pubmed/36983236 http://dx.doi.org/10.3390/jcm12062235 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Penna, Alessio Magliocca, Aurora Merigo, Giulia Stirparo, Giuseppe Silvestri, Ivan Fumagalli, Francesca Ristagno, Giuseppe One-Year Review in Cardiac Arrest: The 2022 Randomized Controlled Trials |
title | One-Year Review in Cardiac Arrest: The 2022 Randomized Controlled Trials |
title_full | One-Year Review in Cardiac Arrest: The 2022 Randomized Controlled Trials |
title_fullStr | One-Year Review in Cardiac Arrest: The 2022 Randomized Controlled Trials |
title_full_unstemmed | One-Year Review in Cardiac Arrest: The 2022 Randomized Controlled Trials |
title_short | One-Year Review in Cardiac Arrest: The 2022 Randomized Controlled Trials |
title_sort | one-year review in cardiac arrest: the 2022 randomized controlled trials |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054058/ https://www.ncbi.nlm.nih.gov/pubmed/36983236 http://dx.doi.org/10.3390/jcm12062235 |
work_keys_str_mv | AT pennaalessio oneyearreviewincardiacarrestthe2022randomizedcontrolledtrials AT maglioccaaurora oneyearreviewincardiacarrestthe2022randomizedcontrolledtrials AT merigogiulia oneyearreviewincardiacarrestthe2022randomizedcontrolledtrials AT stirparogiuseppe oneyearreviewincardiacarrestthe2022randomizedcontrolledtrials AT silvestriivan oneyearreviewincardiacarrestthe2022randomizedcontrolledtrials AT fumagallifrancesca oneyearreviewincardiacarrestthe2022randomizedcontrolledtrials AT ristagnogiuseppe oneyearreviewincardiacarrestthe2022randomizedcontrolledtrials |